Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$14.93
+2.9%
$13.61
$10.45
$21.69
$5.29B0.62984,318 shs935,840 shs
NovoCure Limited stock logo
NVCR
NovoCure
$12.43
+4.4%
$14.75
$10.87
$34.13
$1.39B0.612.07 million shs1.44 million shs
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
$68.57
-1.8%
$81.95
$41.50
$90.32
$3.64B-2.561.65 million shs1.15 million shs
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$119.85
+0.9%
$121.65
$55.00
$177.37
$4.09B2.091.24 million shs1.03 million shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.00%+2.79%+6.19%+32.23%-7.47%
NovoCure Limited stock logo
NVCR
NovoCure
0.00%+5.97%-0.88%-32.96%-28.97%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
0.00%-4.27%-22.11%-10.82%+32.20%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
0.00%-6.04%+12.23%-3.54%-30.70%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
1.6965 of 5 stars
2.12.00.00.01.90.02.5
NovoCure Limited stock logo
NVCR
NovoCure
4.1187 of 5 stars
3.32.00.04.52.63.30.0
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
4.5796 of 5 stars
4.51.00.04.62.72.50.6
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
2.8326 of 5 stars
2.42.00.00.03.72.51.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
2.18
Hold$15.564.22% Upside
NovoCure Limited stock logo
NVCR
NovoCure
2.57
Moderate Buy$28.79131.58% Upside
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3.08
Buy$115.0967.84% Upside
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
2.78
Moderate Buy$123.002.63% Upside

Current Analyst Ratings Breakdown

Latest NVCR, BLCO, SLNO, and TMDX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/20/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$123.00
8/18/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$100.00 ➝ $110.00
8/12/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
8/7/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
8/7/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$97.00 ➝ $106.00
8/7/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$105.00 ➝ $110.00
8/1/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$12.00 ➝ $13.00
8/1/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$115.00 ➝ $123.00
7/31/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $16.00
7/31/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$12.00 ➝ $15.00
7/25/2025
NovoCure Limited stock logo
NVCR
NovoCure
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Equal Weight$40.00 ➝ $14.50
(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$4.79B1.10$1.87 per share7.98$18.39 per share0.81
NovoCure Limited stock logo
NVCR
NovoCure
$605.22M2.30N/AN/A$3.13 per share3.97
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/AN/AN/AN/A$4.52 per shareN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$441.54M9.25$1.65 per share72.84$9.33 per share12.85
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
-$317M-$0.78N/A15.551.52-5.58%2.33%1.12%10/29/2025 (Estimated)
NovoCure Limited stock logo
NVCR
NovoCure
-$168.63M-$1.56N/AN/AN/A-27.13%-47.74%-13.79%10/29/2025 (Estimated)
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$175.85M-$4.14N/AN/AN/AN/A-73.74%-56.67%11/5/2025 (Estimated)
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$35.46M$1.9362.1083.81N/A13.49%28.02%8.64%10/27/2025 (Estimated)

Latest NVCR, BLCO, SLNO, and TMDX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$0.53-$0.09+$0.44-$0.09$3.91 million$32.66 million
7/30/2025Q2 2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$0.06$0.07+$0.01-$0.18$1.25 billion$1.28 billion
7/30/2025Q2 2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$0.48$0.92+$0.44$0.92$146.64 million$157.37 million
7/24/2025Q2 2025
NovoCure Limited stock logo
NVCR
NovoCure
-$0.39-$0.36+$0.03-$0.36$153.87 million$158.80 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
N/AN/AN/AN/AN/A
NovoCure Limited stock logo
NVCR
NovoCure
N/AN/AN/AN/AN/A
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/AN/AN/AN/AN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.76
1.55
0.98
NovoCure Limited stock logo
NVCR
NovoCure
0.28
1.45
1.39
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
0.21
15.13
15.01
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
1.61
9.86
9.17

Institutional Ownership

CompanyInstitutional Ownership
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
11.07%
NovoCure Limited stock logo
NVCR
NovoCure
84.61%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
97.42%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
99.67%

Insider Ownership

CompanyInsider Ownership
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.76%
NovoCure Limited stock logo
NVCR
NovoCure
5.52%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
6.40%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
7.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
13,500353.99 million351.30 millionOptionable
NovoCure Limited stock logo
NVCR
NovoCure
1,488111.80 million105.63 millionOptionable
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3053.15 million49.74 millionOptionable
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
21034.09 million31.70 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bausch + Lomb stock logo

Bausch + Lomb NYSE:BLCO

$14.92 +0.43 (+2.93%)
Closing price 08/22/2025 03:59 PM Eastern
Extended Trading
$14.92 0.00 (0.00%)
As of 08/22/2025 07:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

NovoCure stock logo

NovoCure NASDAQ:NVCR

$12.43 +0.52 (+4.37%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$12.43 0.00 (0.00%)
As of 08/22/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Soleno Therapeutics stock logo

Soleno Therapeutics NASDAQ:SLNO

$68.57 -1.23 (-1.76%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$68.60 +0.03 (+0.04%)
As of 08/22/2025 04:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

TransMedics Group stock logo

TransMedics Group NASDAQ:TMDX

$119.85 +1.04 (+0.88%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$119.66 -0.18 (-0.15%)
As of 08/22/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.